Core Viewpoint - Appili Therapeutics has successfully re-launched LIKMEZ™ (ATI-1501), a metronidazole oral suspension, and is actively pursuing funding opportunities to support its development programs and enhance its market position [2][3][14]. Group 1: Product Development and Market Position - LIKMEZ™ (ATI-1501) is the first FDA-approved, ready-to-use liquid oral suspension of metronidazole, specifically designed for patients who have difficulty swallowing tablets or are sensitive to taste [3][4]. - The re-launch of LIKMEZ follows new patent coverage extending to 2039, marking a significant milestone for the company and its partner, Saptalis Pharmaceuticals [2]. - Appili is focused on driving continued sales of LIKMEZ while advancing other product candidates, including ATI-1701 and ATI-1801 [3]. Group 2: Funding and Financial Performance - The company has submitted five non-dilutive funding proposals to the U.S. government, with a total potential value of up to US$125 million, aimed at supporting the development of critical infectious disease products [3][14]. - For the fiscal year ended March 31, 2025, Appili reported a net loss of CAD 2.6 million, which is an improvement from a net loss of CAD 3.8 million in the previous year, primarily due to increased government assistance and other income [19][20]. - As of March 31, 2025, the company had cash reserves of CAD 1.2 million, a significant increase from CAD 0.1 million a year earlier, indicating improved liquidity [21]. Group 3: Research and Development Progress - ATI-1701, a biodefense vaccine candidate for tularemia, has received approximately US$11.6 million in funding from the U.S. Air Force Academy and has shown promising results in providing protection against lethal tularemia [5][6]. - The company is actively pursuing additional funding and partnership opportunities for ATI-1801, a topical antiparasitic product that has received Orphan Drug Designation from the FDA [10][13]. - Appili has successfully completed technology transfer for the ATI-1701 manufacturing process, supporting future development activities [8].

Core Insights - Oncotelic Therapeutics has published a peer-reviewed research article identifying TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC) [1][2] - The study highlights the potential of TGFB2 methylation to improve overall survival in patients with low CD8+ T-cell infiltration [2][3] Group 1: Research Findings - PDAC is characterized as one of the most lethal cancers with limited treatment options, primarily relying on cytotoxic regimens like FOLFIRINOX [2] - High TGFB2 methylation combined with low expression of immune markers such as CD3D, LCK, and HLA-DRA correlates with a median overall survival exceeding 50 months [3] - The study emphasizes the need to profile TGFB1, TGFB2, and TGFB3 methylation to better understand tumor immune status and select candidates for immunotherapy in resistant "cold" tumors [4] Group 2: Company Commentary - Dr. Sanjive Qazi, the lead author, stated that the discovery enhances understanding of the TGFB gene complex in PDAC, particularly in immunologically cold tumors, supporting further clinical development of OT-101 [5] - Scott Myers highlighted the role of the AI-powered chatbot platform PDAOAI in accelerating scientific discovery through literature mining and analysis [5] - Dr. Michael Potts noted that large language models like PDAOAI are transforming the identification and interpretation of biomedical insights [5] Group 3: Company Background - Oncotelic Therapeutics, originally formed as OXiGENE, Inc. in 1988, has undergone several name changes and is focused on oncology drug development, particularly for rare pediatric cancers [7] - The company has a 45% stake in GMP Biotechnology Limited, which is involved in the development of therapies for various cancers, including Diffuse Intrinsic Pontine Glioma (DIPG) and Acute Myeloid Leukemia (AML) [7] - Oncotelic also acquired PointR Data Inc. to build an AI-driven biotechnology company, further expanding its capabilities in drug development [7]

2025.06. 25 本文字数：3977，阅读时长大约6分钟 作者 | 第一财经 缪琦 站在"十四五"的收官之年回望过去5年，全球经济波动和价值链重构之下，中国在吸引外资上出现了 从高增长到下降再到降幅收窄的量变，也发生了结构性的调整与质变，过程不乏挑战，却也彰显出韧 性。 上海社科院经济研究所研究室主任詹宇波告诉第一财经，"十四五"期间是观察外资变化的关键观测时 段。从此前外资在技术上占有优势，中国以引入先进技术资本的心态提供配套支持，到如今中国诸多 方面都在动荡中取得了积极且长足的进步，不管是中国看待外资还是外资看待中国市场，彼此的心态 都发生了微妙变化，也越来越多地"可以平视"，这是理解当前中国吸引外资现状与未来趋势的重要背 景。 今年5月下旬，英伟达创始人黄仁勋在一档谈话节目中表示："我们对中国市场的承诺始终不变……认 为可以靠其他市场的崛起来取代中国市场的想法并不符合逻辑。那个市场变化迅速，充满活力。" 引资规模始终保持高位 于2021年发布的《中华人民共和国国民经济和社会发展第十四个五年规划和2035年远景目标纲要》 （下称"'十四五'规划"）提出，更大力度吸引和利用外资，有序推进电信、互联网、 ...

每周精选 --- weekly mash - Market Insights 市场洞察 weekly mash - 每周简报 - A few charts / thoughts, without extensive commentary, in a week that felt like one of the quieter weeks in markets year-to-date – in spite of all the geopolitical focus on the evolving situation in the Middle East : 本周市场相对平静，尽管中东局势不断演变引发⼴泛的地缘政治关注，以下是⼀些图表和思考， 未做过多评论 ： 1. A lot of ink and intellectual horsepower has been deployed around the theme of US exceptionalism, USD strength and US asset performance. In conversations with a large Nordic a ...

伊朗报道称，首都警方逮捕了一名摩萨德特工，该特工使用WhatsApp向国外情报人员发送防空部署位 置。 ...

Following the Second Pending Contract for Protective Plates, Our Enhanced Proprietary Graphene Technology Will be Initiated for Coating of the ArmorEL CENTRO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Premier Graphene Inc. (OTC: BIEI), formerly Premier Biomedical Inc., announced today, along with its affiliate HGI Industrial Technologies SAPI, and Nevada Ballistic Armor Corp., its launch of a multinational joint venture producing highly protective body armor for military. As part of this collaboration, Prem ...

Core Insights - Premier Graphene Inc. has launched a multinational joint venture with HGI Industrial Technologies and Nevada Ballistic Armor Corp. to produce advanced body armor for military applications [1][3] - The joint venture has successfully delivered armored plates for testing in a Latin American country, achieving NIJ certification in the U.S. [2][3] - Future contracts valued at $18 million are anticipated, with three additional contracts pending, indicating strong market potential [3] Company Overview - Premier Graphene Inc. is focused on developing advanced materials, particularly in graphene technology, for various sectors including defense [7] - HGI Industrial Technologies specializes in processing industrial hemp into bio graphene and manufacturing ballistic protection solutions [7] - Nevada Ballistic Armor Corp. is recognized for its ballistic protection solutions and has established connections that enhance the manufacturing process for military applications [9] Product Development - The armored plates will incorporate proprietary industrial hemp graphene and other advanced materials from affiliated entities [5] - Future iterations of the body armor will include innovative coatings and testing methodologies to enhance performance [5][6] - The collaboration aims to push the boundaries of next-generation body armor solutions through advanced materials and manufacturing techniques [6]

New Sapiens CoreSuite release empowers life insurers, agents, customers, and administrators with greater speed, intelligence, and deeper customer engagement via gen AIROCHELLE PARK, N.J., June 17, 2025 /PRNewswire/ -- Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, announced the latest release of CoreSuite a comprehensive policy administration system for life, pensions, and annuities. Life insurers can now streamline ...

在合作推进过程中,双方团队展现出了卓越的专业素养与协作精神。通过紧密沟通与高效协作,成功推出 了一系列创新金融产品与服务,不仅满足了市场多元化的需求,更为客户提供了更加优质、全面的金融解 决方案。在投资管理方面,双方结合各自在全球市场的研究经验与投资策略,为客户实现了资产的稳健增 值;在金融科技领域,共同投入研发资源,推动数字化金融服务的创新发展,提升了金融服务的效率与便捷 性。这些努力使得双方在合作中取得了令人瞩目的成果,赢得了市场的高度认可与客户的广泛赞誉。 左为SapienGroup运营CEO:Sheetal Jiang,右为弈衡国际行政总裁邹恩先生 在全球金融格局不断演变的时代背景下,香港弈衡国际与 SapienGruop(慧衍集团)的合作交流备受瞩目。 2025 年 5 月 9 日,香港弈衡国际行政总裁邹恩先生再度踏上前往澳洲的考察之旅,旨在进一步深化与 SapienGruop(慧衍集团)的合作关系,探索更广阔的金融合作前景。 回溯到 2023 年,弈衡国际(JiutongGroup)与 SapienGruop(慧衍集团)凭借敏锐的市场洞察力与战略前瞻性, 达成了意义深远的合作协议。双方携手将合作领 ...

Q1 2025 Investor Presentation Roni Giladi, CFO Yaffa Cohen-Ifrah, CMO and Head of IR May 8, 2025 Forward Looking Statements Certain matters discussed in this presentation, that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as i ...